Editas Medicine, Inc. vs Merck & Company, Inc. — Stock Comparison

EDIT
Editas Medicine, Inc.
$2.90
▼ 3.33%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 4.9/10

Q·Score Breakdown

4.9
Bearish
Overall
6.7
Neutral
1.6
Quality
6.2
7.7
Health
7
4.3
Growth
6.2
6.8
Valuation
7.2
5.2
Sentiment
7.1
EDIT

Healthy balance sheet and financial position.

low return on equity (-198%).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

HOLD
Target $5.72 (+97.3%)
9 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

EDIT
MRK
Trailing P/E
31.5×
-3.3×
Forward P/E
11.5×
0.0%
Profit Margin
13.6%
-122.0%
Gross Margin
76.6%
-198.1%
ROE
-19.2%
Revenue Growth
4.9%
Earnings Growth
2.04
Beta
0.28
Price / Book
$284M
Market Cap
$277.0B
$1 – $5
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →